艾德生物收盘下跌1.32%，滚动市盈率28.21倍，总市值79.32亿元

Group 1 - The core viewpoint of the news is that Aide Biological's stock is underperforming compared to its industry peers, with a current PE ratio of 28.21, significantly lower than the industry average of 48.71 [1][2] - Aide Biological's market capitalization is reported at 7.932 billion yuan, ranking 65th in the medical device industry based on PE ratio [1][2] - The company experienced a net outflow of 9.8921 million yuan in principal funds on May 22, with a total outflow of 8.7322 million yuan over the past five days [1] Group 2 - Aide Biological specializes in tumor gene testing reagents, software, and supporting instruments, as well as providing testing services and drug clinical research services [1] - For the first quarter of 2025, Aide Biological reported revenue of 272 million yuan, a year-on-year increase of 16.63%, and a net profit of 90.4718 million yuan, reflecting a year-on-year growth of 40.92% [1] - The company's gross profit margin stands at 83.48% [1]